Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
12:20:47 EDT Fri 19 Apr 2024
Enter Symbol
or Name
USA
CA



Z:TAK - TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS - http://www.takeda.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
TAK - Z4.013.24·13.252.213.245+0.0850.6301.83,8921,05513.20  13.26  13.19517.115  13.1112:02:55Apr 1815 min RT 2¢

Recent Trades - Last 10 of 1055
Time ETExPriceChangeVolume
12:03:04Z13.2450.085100
12:03:04Z13.2450.085100
12:03:04Z13.2450.08510
12:02:55Z13.240.081
12:02:19Z13.2480.0881
12:02:08Z13.24090.080918
12:02:08Z13.24920.08922
12:01:27Z13.250.0993
12:01:07Z13.250.0911
12:01:07Z13.250.0989

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-18 19:00U:TAKNews ReleaseU.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO(TM) (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease
2024-04-08 08:00U:TAKNews ReleaseTakeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food
2024-03-26 19:07U:TAKNews ReleaseTakeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
2024-03-26 08:00U:TAKNews ReleaseTakeda Announces Approval of ADZYNMA(TM) Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
2024-03-19 12:20U:TAKNews ReleaseTakeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG(TM) (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
2024-03-19 06:31U:TAKNews ReleaseCENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
2024-03-13 08:00U:TAKNews ReleaseTakeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
2024-02-26 23:30U:TAKNews ReleaseTakeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
2024-02-26 07:00U:TAKNews ReleaseChampioning Rare Voices on Rare Disease Day
2024-02-12 08:00U:TAKNews ReleaseFDA Approves Takeda ¢ € ™s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)
2024-02-08 18:00U:TAKNews ReleaseTakeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024
2024-02-01 01:54U:TAKNews ReleaseTakeda Announces Chief Financial Officer Succession
2024-01-29 11:10U:TAKNews ReleaseTakeda ¢ € ™s GAMMAGARD LIQUID ‚ ® Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
2024-01-29 02:00U:TAKNews ReleaseTakeda ¢ € ™s HYQVIA ‚ ® Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
2024-01-25 17:00U:TAKNews ReleaseCognizant Helping to Modernize Infrastructure and Application Management as Part of Takeda's Digital Transformation
2024-01-18 07:00U:TAKNews ReleaseTakeda Named Global Top Employer for Seventh Consecutive Year
2024-01-16 08:00U:TAKNews ReleaseU.S. FDA Approves Takeda ¢ € ™s HYQVIA ‚ ® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
2023-12-21 16:00U:TAKNews ReleaseTakeda Announces China NMPA Approval of LIVTENCITY ‚ ® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies
2023-12-20 07:01U:TAKNews ReleaseTakeda Enters Into Two-Year Contract with Canadian Blood Services for GLASSIA ®, Treatment for Rare form of Emphysema